The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bajtay, Z.
Right arrow Articles by Dierich, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bajtay, Z.
Right arrow Articles by Dierich, M. P.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2004, 173: 4775-4778.
Copyright © 2004 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3, CD11b/CD18)

Zsuzsa Bajtay*, Cornelia Speth*, Anna Erdei{dagger} and Manfred P. Dierich1,*

* Department of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University and Ludwig-Boltzman-Institute for AIDS Research, Innsbruck, Austria; and {dagger} Department of Immunology and Research Group of the Hungarian Academy of Sciences, Eötvös Loránd University, Budapest, Hungary


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In the present study, we demonstrate that macrophage-tropic HIV-1 opsonized by complement and limited amounts of anti-HIV-IgG causes up to 10-fold higher productive infection of human monocyte-derived dendritic cells than HIV treated with medium or HIV opsonized by Ab only. Enhanced infection is completely abolished by a mAb specific for the ligand-binding site of CD11b (i.e., {alpha}-chain of complement receptor 3, receptor for iC3b), proving the importance of complement receptor 3 in this process. Inhibition of complement activation by EDTA also prevents enhanced infection, further demonstrating the role of complement in virus uptake and productive infection. Since HIV is, even in the absence of Abs, regularly opsonized by complement, most probably the above-described mechanism plays a role during in vivo primary infection.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Effector functions of the complement system, one of the main components of natural immunity, include opsonization leading to enhanced phagocytosis and lysis of microbes. HIV is able to activate complement both in the absence and, even more so, in the presence of virus-specific Abs. Following binding of C1q to gp41 of HIV, the classical pathway of complement activation is initiated (1), while the lectin-dependent activation is initiated by the interaction of gp120 and gp41 with the mannan-binding lectin (2). Covalent binding of C3 fragments to the viral envelope allows binding of HIV to cells expressing receptors for C3b (complement receptor (CR)2 1, CD35), iC3b (CR3, CD11b/CD18; CR4, CD11c/CD18), and C3d, C3dg (CR2, CD21). HIV-1 infection of human lymphocytes and monocytes/macrophages is greatly enhanced by opsonization of the virus with complement (3, 4, 5).

In general, microorganisms coated with C3 fragments acquire the capacity for high binding to CR1–4 (3, 4, 5, 6, 7). CR3 and CR4 are members of the {beta}2-integrin family, are expressed on several cell types, including phagocytic cells, and play an important role in phagocytosis of opsonized pathogens. It has been shown that dendritic cells (DCs) in normal human skin as well as monocyte-derived DCs (MDCs) differentiated in vitro express CD11b (8). Regarding the expression of CD11c, two major populations are present in the body: the CD11c+ myeloid DCs, and the CD11c– plasmacytoid DCs. CR3 and adhesion molecules are documented to facilitate viral entry into different target cells (9, 10).

CD14+ human monocytes can develop into MDCs in vitro by culturing in medium containing GM-CSF and IL-4. By day 5 in culture, the cells have the characteristics of immature DCs (imMDCs) and can be further induced to mature DCs by inflammatory stimulus such as LPS. Maturation rapidly induces DCs to express costimulatory molecules, such as CD80 and CD86, necessary for the activation of naive T cells (11). Targets of HIV during primary in vivo infection are macrophages and DCs, which are predominantly permissive for R5 viruses (12). imMDCs can be productively infected with R5 viruses and the virus produced by these cells is able to infect T cells. Mature DCs do not produce viral particles, still they are able to transmit both R5 and X4 viruses to T cells (13).

Our observation that complement opsonization of HIV causes a distinctively productive infection of DCs has not yet been documented. In this study, we report that CR3 plays a crucial role in the productive infection of imMDCs by C3-opsonized HIV.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Media, Abs, cytokines

Anti-human (hu) C3c, anti-huC3d, and anti-huIgG rabbit polyclonal Abs and FITC-conjugated goat anti-mouse Ig polyclonal Ab were obtained from DakoCytomation (Glostrup, Denmark). Mouse mAbs used in this work were as follows: anti-CD4, anti-CD86, anti-CD83, anti-CD14, anti-CCR5, anti-CD11c (BD Pharmingen, San Diego, CA) anti-CD18 (OKM-1); hybridoma supernatants and mouse IgG1 isotype control were used at 10 µg/ml. mAb TMG6-5 blocking anti-CD11b (14) was kindly provided by I. Andó (Biological Research Center, Szeged, Hungary).

DC cultures

MDCs were generated in vitro by culturing monocytes (15, 16). Briefly, PBMCs were obtained by the standard Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) method. Monocytes were isolated by adherence using gelatin-coated petri dishes (17). The purity of the monocyte suspension was 90–95%, as judged by FACS analysis. Differentiation of monocytes into imMDCs was induced by culturing in RPMI 1640 medium (Invitrogen Life Technologies, Grand Island, N.Y.) supplemented with 1600 U/ml recombinant human (rh) GM-CSF (Novartis, Vienna, Austria), and 1500 U/ml rhIL-4 (PromoCell, Heidelberg, Germany), 10% heat-inactivated FCS (Invitrogen Life Technologies), 2 mM L-glutamine, and 50 µg/ml gentamicin (Sigma-Aldrich, St. Louis, MO) in 24-well tissue culture plates (Costar, Cambridge, MA). Culture medium was refreshed at days 5 and 7 and supplemented with cytokines at days 2, 5, and 7. imMDCs were CD14–, CD80+, CD86+, CD83–, CD11b+, CD11c+, HLA-DR+, CD4low, and CCR5low (12, 18). imMDCs were used for virus binding and infectious experiments on day 7 of culture. Occasionally, in vitro maturation of MDCs was induced by 100 ng/ml LPS (Sigma-Aldrich).

HIV sources, p24 ELISA

The M-tropic HIV-1 primary isolate 92UG037 (subtypeA/A, R5 tropism) was kindly provided by G. Stiegler (Institute of Applied Microbiology, Vienna, Austria). Virus stock was produced by PHA-activated PBMCs of healthy donors and maintained in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. The virus was pelleted at 20,000 rpm by ultracentrifugation and stored at –80°C. For assessment of virus quantity, the p24 capture ELISA was used, developed at the Institute of Applied Microbiology in Vienna (19); it was performed as described earlier (18).

Opsonization of HIV, virus capture assay

Opsonized virus was prepared in the presence of anti-HIV IgG (purified from pooled sera of HIV+ patients) and normal human serum as complement source (HIVIgG + C) or in the presence of anti-HIV IgG alone (HIVIgG). Control samples were prepared in medium only (HIV). For opsonization, 1 µg/ml p24 HIV was incubated with 50 µg/ml anti-HIV IgG (HIVIgG) or with anti-HIV IgG and 10-fold diluted normal human serum (HIVIgG + C) for 1 h at 37°C. In some experiments, EDTA (20 mM) was used to inhibit complement activation (HIVIgG + C + EDTA). The opsonized virus was washed and pelleted by ultracentrifuge; aliquots were stored at –80°C and thawed once before the experiments. Opsonization was detected by a virus capture ELISA system. Preparations containing opsonized HIV were incubated in wells coated by Abs specific for huIgG, or for complement fragments C3c and C3d, respectively. Captured HIV was lysed in detergent and transferred to anti-p24-coated plates. After incubation with anti-HIV IgG, the virus bound intensively to the anti-IgG coat. As a result of classical pathway activation of the complement system, strong C3 and low (if any) IgG deposition were detected in the HIVIgG + C samples, suggesting poor accessibility of the IgG on HIVIg + C.

Binding of HIV to DC

To demonstrate binding of HIV, 5 x 105 imMDCs were incubated with 10 ng/ml p24 HIV, HIVIgG, HIVIgG + C, and HIVIgG + C + EDTA for 1 h at 37°C. Then nonbound virus was removed by washing two times with warm medium. The cells were lysed with 1% Nonidet P-40 and the amount of p24 Ag was determined by p24 ELISA. To determine the effect of proteinase K (Sigma-Aldrich) on HIV entry, the cells were held in the presence of 10 µg/ml enzyme before determination of p24. All data are presented as mean values ± SD.

Infection of MDCs with HIV-1

To determine the infectivity of HIV, 5 x 105 imMDCs were incubated with 10 ng/ml p24 HIV, HIVIgG, HIVIgG + C, and HIVIgG + C + EDTA, respectively, for 8 h, then the cells were washed two times with warm medium and placed back into culture in 24-well plates for an additional 15 days. Twenty-five percent of medium was replaced with rhIL-4 and rhGM-CSF every third day. The amount of virus produced by the cells was estimated by p24 ELISA from the supernatants every other day.

Flow cytometry

The expression of surface molecules of cells was determined at day 7 of culture. Briefly, 5 x 104 cells were washed with 1% BSA-0,1% NaN3-PBS and incubated with Abs reacting with CD80, CD86, CD83, CD11b, CD11c, CD18, HLA-DR, CD14, CD4, and CCR5, followed by FITC-labeled anti-mouse IgG. As control, samples were labeled with isotype-matched control Abs. After staining, the cells were washed and fixed in PBS containing 1% Formalin and 0,1% NaN3 and analyzed by flow cytometry (FACScan; BD Biosciences, Mountain View, CA).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Expression of CR3 during maturation of DCs

It has been demonstrated in earlier studies that DCs do not possess CR1 and CR2, while they express CR3 and CR4 (18, 20, 21). Since opsonization is known to influence viral infection (4, 5, 22) we aimed to clarify whether CR3, mediating the uptake of C-coated particles by several cell types, is involved in a similar process of MDCs. For these experiments we used the Ab TMG6-5, which interacts with the receptor’s ligand binding site. Fig. 1 shows that TMG6-5 binds to imMDCs and mature MDCs (maMDCs) in a similar fashion. It is also seen in Fig. 1 that the percentage of CR3+ cells is decreased in maMDCs.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 1. Surface expression of CD11b and CD18 of imMDCs and maMDCs at day 7. Shaded histograms represent the binding of CD11b- and CD18-specific Abs. Open histograms represent isotype-matched controls. Mean fluorescence intensity values are shown. The data are representative of seven independent experiments.

 
Effect of opsonization by complement on binding of HIV-1 to imMDCs

To investigate the binding of C-opsonized HIV, imMDCs were incubated with HIVIgG + C and for control with HIV, HIVIgG, and HIVIgG + C + EDTA. After removing nonbound virus, cells were lysed and the amount of p24 Ag was determined by ELISA. Fig. 2 shows that HIVIgG + C binds more efficiently to imMDCs than HIVIgG. This enhancement was abolished when complement activation and opsonization were inhibited by 20 mM EDTA.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 2. Binding of nonopsonized and opsonized HIV to imMDCs. imMDCs at day 7 were incubated with HIV, HIVIgG, HIVIgG + C, and HIVIgG + C + EDTA for 1 h at 37°C. The concentration of p24 Ag was determined from the cell lysates after removing nonbound viruses. The data are representative of six independent experiments.

 
Effect of opsonization of HIV by complement on infection of imMDCs

Infection of human monocytes and macrophages with HIV is greatly facilitated by opsonization of the virus with C3 fragments (5, 22). To test whether infection of imMDCs by HIV is influenced by opsonization, the cells were cultured with the HIV-1 primary isolate pretreated with IgG and complement. Culture supernatants were collected every other day, centrifuged, and the concentration of free virions was estimated by p24 ELISA. As demonstrated in Fig. 3, opsonization with HIV-specific IgG and human complement caused >10-fold enhancement in HIV production by MDCs, as compared with nonopsonized HIV or HIV opsonized with specific IgG only. Virus particles treated with serum in the presence of 20 mM EDTA caused low productive infection similar to the medium-treated control.



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 3. Productive infection of imMDCs by opsonized HIV-1. imMDCs were infected with HIV, HIVIgG, HIVIgG + C, and HIVIgG + C + EDTA at day 7. The amount of free virions was measured by p24 ELISA from the supernatants on days as indicated. The data are representative of five independent experiments.

 
Treatment of imMDCs with CD11b-specific Ab or with proteinase K and their effect on infection by complement-opsonized HIV-1

To investigate the role of CR3 in the uptake of the opsonized virus, the cells were preincubated with mAb TMG6-5, which interacts with the ligand binding site of CD11b. As shown in Fig. 4A, the Ab reduced binding of HIVIgG + C to background level. Also, as seen in Fig. 4B, the productive infection of MDCs tested on day 14 was almost completely abolished by the CR3-specific Ab, while the isotype-matched control Ab showed no effect. To demonstrate that uptake of opsonized HIV was the key to productive infection, cells were treated with proteinase K before p24 measurement. As shown in Fig. 4A, this enzyme treatment resulted in a significant loss of HIV associated with MDCs.



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 4. The effect of anti-CD11b mAb (TMG6-5) and proteinase K on binding of opsonized HIV and productive infection of imMDCs. A, imMDCs, pretreated with mAb TMG6-5 and, as control, with isotype-matched control Ab were incubated with HIVIgG + C. The effect of proteinase K was assessed after treating the cells in the presence of 10 µg/ml enzyme. The amount of p24 Ag was determined by p24 ELISA. All data are presented as mean values ± SD. B, To determine infectivity of imMDCs pretreated with mAb TMG6-5 and, as control, with isotype-matched control Ab were incubated with HIVIgG + C, and cells were placed back into culture after washing. The amount of virus produced by the cells was estimated by p24 ELISA from the supernatants on days as indicated. The data are representative of five independent experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
It is generally accepted that opsonization by complement enhances HIV uptake by CR-bearing cells, including MDCs. In this study, we show that opsonization of HIV with complement (and IgG) caused a slight increase in binding to MDCs but a 10-fold higher productive infection of imMDCs. This describes for the first time the crucial role of CR3 in this process. In contrast to CR3, DC-specific ICAM-3-grabbing nonintegrin, another important attachment receptor for HIV on DCs, is known to bind HIV and to operate in transmission of the virus to CD4+ T cells (23); however, this does not induce productive infection of DCs. The key role of CR3 in efficient uptake of opsonized HIV by imMDCs was proven by inhibition with CD11b-specific mAbs. We also found that productive infection was strongly inhibited by anti-CD4 mAb (data not shown), suggesting that even in CR3-mediated enhancement of productive infection CD4 plays a critical role. In other studies, inhibition by anti-CR3 mAb of monocyte infection (18, 22) and partial inhibition by CD11b-specific Abs (10) of PBMC infection with HIV were observed.

Opsonization of HIV by complement occurs in human serum by direct binding of C1q already in the absence of anti-HIV Abs (1, 2), but is much more pronounced after binding of Abs on the surface of HIV. Complement is also known to be activated by HIV upon direct binding of MBL; the activation of the alternative pathway in HIV-infected patients has also been observed (24). Other studies, however, show that intact HIV activates complement only in the presence of antiviral Abs (25, 26). Sensitivity to complement-mediated lysis is influenced by the actual composition of the viral membrane, as in vitro studies demonstrated that some primary isolates of HIV are highly resistant to complement-mediated lysis due to the incorporation of host cell-derived complement control proteins, including CD46, CD55, and CD59 (27, 28).

Since HIV particles in infected patients are early on coated with complement at the site of infection, imDCs could be the first target of infection. As reported by Shi et al. (29), clustering of CR3 on monocytic cells recruits a Toll/IL-1R family-like signaling cascade, interacting with IL-1R-associated kinase 1 to induce NF-{kappa}B activity. HIV opsonized with C3 fragments represents a multimerized ligand. In our studies its binding most probably leads to clustering of CR3 and thus supports NF-{kappa}B signaling. This may then direct regulation of genes encoding for cytokines, chemokines, adhesion molecules, and enzymes, thereby modulating several cellular functions.

Although the precise mechanism through which complement coating of HIV leads to a 30% increase in HIV binding to CR3 on imMDCs but to a 10-fold increase in virus production remains unclear. The following hypothesis may be offered: Binding of complement-coated HIV to CR3 may induce specific signaling cascades and direct HIV to compartments in DCs which are favorable for productive infection. Both aspects are subjects of future research.


   Acknowledgments
 
We thank C. Larcher for helpful discussion and the Austrian Research Fond (FWF, P15379, and P15375), the state of Tyrol, and the Ludwig-Boltzmann Society for support.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Address correspondence and reprint requests to Prof. Manfred P. Dierich, Department of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University and Ludwig-Boltzman-Institute for AIDS Research, Fritz-Pregl-Strasse 3, A-6020 Innsbruck, Austria. E-mail address: hygiene{at}uibk.ac.at Back

2 Abbreviations used in this paper: CR, complement receptor; DC, dendritic cell; MDC, monocyte-derived DC; imMDC, immature MDC; hu, human; rh, recombinant human; maMDC, mature MDC. Back

Received for publication June 8, 2004. Accepted for publication August 18, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Ebenbichler, C. F., N. M. Thielens, R. Vornhagen, P. Marschang, G. J. Arlaud, M. P. Dierich. 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174:1417.[Abstract/Free Full Text]
  2. Dierich, M. P., C. F. Ebenbichler, P. Marschang, G. Fust, N. M. Thielens, G. J. Arlaud. 1993. HIV and human complement: mechanisms of interaction and biological implication. Immunol. Today 14:435.[Medline]
  3. Delibrias, C. C, M. D. Kazatchkine, E. Fischer. 1993. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand. J. Immunol. 38:183.[Medline]
  4. Legendre, C., G. Gras, R. Krzysiek, P. Galanaud, Y. Richard, D. Dormont. 1996. Mechanisms of opsonized HIV entry in normal B lymphocytes. FEBS Lett. 381:227.[Medline]
  5. Thieblemont, N., N. Haeffner-Cavaillon, A. Ledur, J. L’Age-Stehr, H. W. Ziegler-Heitbrock, M. D. Kazatchkine. 1993. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin. Exp. Immunol. 92:106.[Medline]
  6. Erdei, A., G. Füst, J. Gergely. 1991. The role of C3 in the immune response. Immunol. Today 12:332.[Medline]
  7. Gordon, S.. 2002. Pattern recognition receptors: doubling up for the innate immune response. Cell 111:927.[Medline]
  8. Grassi, F., C. Dezutter-Dambuyant, D. McIlroy, C. Jacquet, K. Yoneda, S. Imamura, L. Boumsell, D. Schmitt, B. Autran, P. Debre, A. Hosmalin. 1998. Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules. J. Leukocyte Biol. 64:484.[Abstract]
  9. Hildreth, J. E., R. J. Orentas. 1989. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 244:1075.[Abstract/Free Full Text]
  10. Stoiber, H., I. Frank, M. Spruth, M. Schwendinger, B. Mullauer, J. M. Windisch, R. Schneider, H. Katinger, I. Ando, M. P. Dierich. 1997. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry?. Mol. Immunol. 34:855.[Medline]
  11. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.[Medline]
  12. Zaitseva, M., A. Blauvelt, S. Lee, C. K. Lapham, V. Klaus-Kovtun, H. Mostowski, J. Manischewitz, H. Golding. 1997. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat. Med. 3:1369.[Medline]
  13. Granelli-Piperno, A, E. Delgado, V. Finkel, W. Paxton, R. M. Steinman. 1998. Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J. Virol. 72:2733.[Abstract/Free Full Text]
  14. Uciechowski, P., R. E. Schmidt. 1989. White cell differentiation antigens. W. Knapp, and B. Dörken, and W. R. Gilks, and E. P. Rieber, and R. E. Schmidt, and H. Stein, and A. E. G. von dem Borne, eds. Leukocyte Typing IV 543. Oxford Univ. Press, Oxford, U.K..
  15. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83.[Abstract/Free Full Text]
  16. Sallusto, F., A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor {alpha}. J. Exp. Med. 179:1109.[Abstract/Free Full Text]
  17. Freundlich, B., N. Avdalovic. 1983. Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J. Immunol. Methods 62:31.[Medline]
  18. Kacani, L., I. Frank, M. Spruth, M. G. Schwendinger, B. Mullauer, G. M. Sprinzl, F. Steindl, M. P. Dierich. 1998. Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages. J. Virol. 72:6671.[Abstract/Free Full Text]
  19. Purtscher, M., A. Trkola, G. Gruber, A. Buchacher, R. Predl, F. Steindl, C. Tauer, R. Berger, N. Barrett, A. Jungbauer. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10:1651.[Medline]
  20. Hart, D. N., J. L. McKenzie. 1988. Isolation and characterization of human tonsil dendritic cells. J. Exp. Med. 168:157.[Abstract/Free Full Text]
  21. Stingl, G., E. C. Wolff-Schreiner, W. J. Pichler, F. Gschnait, W. Knapp, K. Wolff. 1977. Epidermal Langerhans cells bear Fc and C3 receptors. Nature 268:245.[Medline]
  22. Bouhlal, H., J. Galon, M. D. Kazatchkine, W. H. Fridman, C. Sautes-Fridman, N. Haeffner Cavaillon. 2001. Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J. Immunol. 166:3377.[Abstract/Free Full Text]
  23. Geijtenbeek, T. B., S. J. van Vliet, A. Engering, B. A. ’t Hart, Y. van Kooyk. 2004. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 22:33.[Medline]
  24. Yefenof, E., T. Magyarlaki, E. M. Fenyo, B. Wahren, E. Klein. 1994. Alternative complement pathway activation by CD4+ T cells of HIV infected individuals: a possible role in AIDS pathogenesis. Int. Immunol. 6:1361.[Abstract/Free Full Text]
  25. June, R. A., S. Z. Schade, M. J. Bankowski, M. Kuhns, A. McNamara, T. F. Lint, A. L. Landay, G. T. Spear. 1991. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 5:269.[Medline]
  26. Sullivan, B. L., E. J. Knopoff, M. Saifuddin, D. M. Takefman, M. N. Saarloos, B. E. Sha, G. T. Spear. 1996. Susceptibility of HIV-1 plasma virus to complement-mediated lysis: evidence for a role in clearance of virus in vivo. J. Immunol. 157:1791.[Abstract]
  27. Stoiber, H., C. Speth, M. P. Dierich. 2003. Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 21:(Suppl. 2):77. Review.
  28. Montefiori, D. C., R. J. Cornell, J. Y. Zhou, J. T. Zhou, V. M. Hirsch, P. R. Johnson. 1994. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205:82.[Medline]
  29. Shi, C., X. Zhang, Z. Chen, M. K. Robinson, D. I. Simon. 2001. Leukocyte integrin Mac-1 recruits Toll/interleukin-1 receptor superfamily signaling intermediates to modulate NF-{kappa}B activity. Circ. Res. 89:859.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Virol.Home page
M. Huber, V. von Wyl, C. G. Ammann, H. Kuster, G. Stiegler, H. Katinger, R. Weber, M. Fischer, H. Stoiber, H. F. Gunthard, et al.
Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked
J. Virol., April 15, 2008; 82(8): 3834 - 3842.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Wilflingseder, Z. Banki, E. Garcia, M. Pruenster, G. Pfister, B. Muellauer, D. S. Nikolic, C. Gassner, C. G. Ammann, M. P. Dierich, et al.
IgG Opsonization of HIV Impedes Provirus Formation in and Infection of Dendritic Cells and Subsequent Long-Term Transfer to T Cells
J. Immunol., June 15, 2007; 178(12): 7840 - 7848.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Bouhlal, N. Chomont, M. Requena, N. Nasreddine, H. Saidi, J. Legoff, M. D. Kazatchkine, L. Belec, and H. Hocini
Opsonization of HIV with Complement Enhances Infection of Dendritic Cells and Viral Transfer to CD4 T Cells in a CR3 and DC-SIGN-Dependent Manner
J. Immunol., January 15, 2007; 178(2): 1086 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Banki, D. Wilflingseder, C. G. Ammann, M. Pruenster, B. Mullauer, K. Hollander, M. Meyer, G. M. Sprinzl, J. van Lunzen, H.-J. Stellbrink, et al.
Factor I-Mediated Processing of Complement Fragments on HIV Immune Complexes Targets HIV to CR2-Expressing B Cells and Facilitates B Cell-Mediated Transmission of Opsonized HIV to T Cells.
J. Immunol., September 1, 2006; 177(5): 3469 - 3476.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. M. I. Aasa-Chapman, S. Holuigue, K. Aubin, M. Wong, N. A. Jones, D. Cornforth, P. Pellegrino, P. Newton, I. Williams, P. Borrow, et al.
Detection of Antibody-Dependent Complement-Mediated Inactivation of both Autologous and Heterologous Virus in Primary Human Immunodeficiency Virus Type 1 Infection
J. Virol., March 1, 2005; 79(5): 2823 - 2830.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
D. R. Greaves and S. Gordon
Thematic review series: The Immune System and Atherogenesis. Recent insights into the biology of macrophage scavenger receptors
J. Lipid Res., January 1, 2005; 46(1): 11 - 20.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bajtay, Z.
Right arrow Articles by Dierich, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bajtay, Z.
Right arrow Articles by Dierich, M. P.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS